{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:41:35Z","timestamp":1782999695756,"version":"3.54.5"},"publisher-location":"Chichester, UK","reference-count":24,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005081.pub2","type":"reference-entry","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T20:10:34Z","timestamp":1147205434000},"source":"Crossref","is-referenced-by-count":20,"title":["Medical and surgical treatment for ocular myasthenia"],"prefix":"10.1002","author":[{"given":"Michael","family":"Benatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,19]]},"reference":[{"issue":"Suppl","key":"10.1002\/14651858.CD005081.pub2-BIB1|cit1","first-page":"S59","article-title":"Intranasal neostigmine as add-on therapy in myasthenia gravis","volume":"243","author":"Badrising","year":"1996","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD005081.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/archneur.1964.00460200010002","article-title":"Corticotropin in treatment of ocular myasthenia - a controlled clinical trial","volume":"11","author":"Mount","year":"1964","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD005081.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever Jr","year":"1983","journal-title":"Annals of Neurology"},{"issue":"17","key":"10.1002\/14651858.CD005081.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005081.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","article-title":"Therapeutic options in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"10","key":"10.1002\/14651858.CD005081.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"issue":"1","key":"10.1002\/14651858.CD005081.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD005081.pub2-BIB9|cit9","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-59259-341-5","volume-title":"Myasthenia gravis and related disorders","author":"Kaminski","year":"2003"},{"issue":"1-2","key":"10.1002\/14651858.CD005081.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2003.09.016","article-title":"Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000","volume":"224","author":"Kawaguchi","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"issue":"8","key":"10.1002\/14651858.CD005081.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Archives of Neurology"},{"issue":"8","key":"10.1002\/14651858.CD005081.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD005081.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"Journal of Neuro-ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-5223(96)70264-7","article-title":"Delayed remission after thymectomy for myasthenia gravis of the purely ocular type","volume":"112","author":"Nakamura","year":"1996","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"key":"10.1002\/14651858.CD005081.pub2-BIB17|cit17","volume-title":"Myasthenia Gravis","author":"Oosterhuis","year":"1997"},{"issue":"7","key":"10.1002\/14651858.CD005081.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ophtha.2007.10.022","article-title":"Long-term outcomes of pediatric ocular myasthenia gravis","volume":"115","author":"Ortiz","year":"2008","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005081.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archneur.60.10.1491-b","article-title":"Development of generalized myasthenia gravis in patients with ocular myasthenia gravis","volume":"60","author":"Papapetropoulos","year":"2003","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD005081.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00000658-198707000-00013","article-title":"Effects of thymectomy in myasthenia gravis","volume":"206","author":"Papatestas","year":"1987","journal-title":"Annals of Surgery"},{"issue":"4","key":"10.1002\/14651858.CD005081.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jnnp.48.4.332","article-title":"Thymectomy in myasthenia with pure ocular symptoms","volume":"48","author":"Schumm","year":"1985","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"9274","key":"10.1002\/14651858.CD005081.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD005081.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005081.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005081.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:44:37Z","timestamp":1628545477000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005081.pub2"}},"subtitle":[],"editor":[{"given":"Michael","family":"Benatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,4,19]]},"references-count":24,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005081.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD005081.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2006,4,19]]}}}